AC Immune (ACIU)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention...
- Open
- 2.600
- High
- 2.650
- Low
- 2.435
- Prev. Close
- 2.580
- Volume
- 237.11K
- Turnover
- 597.87K
- Avg Price
- 2.521
- Bid/Ask Ratio
- -73.91%
- Amplitude
- 8.33%
- 52wk High
- 4.000
- Volume Ratio
- 1.27
- Turnover Ratio
- 0.58%
AC Immune Analyst Rating
View moreForecast & Rating
Aug 20, 2026Price forecast
$8.54223.41%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 16 hours ago
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline
- PUBT · 22 hours ago
AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764
- Market Beat · 2 days ago, 02:00 AM
AC Immune (NASDAQ:ACIU) Stock Passes Above 50-Day Moving Average - Here's Why
- PUBT · Aug 11 at 06:00 AM
AC Immune wins FDA fast-track status for Parkinson’s immunotherapy ACI-7104
- Market Beat · Aug 5 at 01:56 PM
AC Immune (NASDAQ:ACIU) Announces Earnings Results, Misses Estimates By $0.09 EPS
- PUBT · Aug 5 at 06:01 AM
AC Immune IFRS net loss narrows to CHF 12.93 million in H1 FY26; revenue rises to CHF 16.23 million
